Please contact us for formulations using our new NANOMETM nanoparticulate drug delivery system for a wide variety of drugs to overcome major obstacles like poor solubility, poor bioavailability and P-gp mediated efflux. In addition, the NANOMETM drug delivery system reduces adverse side effects and toxicity of chemotherapeutics. NANOME® services, which include research and development of drug delivery systems for taxanes and other cancer treatment drugs, are available.
INTELLECTUAL PROPERTY STATUS
US 8,242,165 B2 issued August 14, 2012.
NANOME (Class 42) Registration No. 3,687,057 issued September 22, 2009.
Some Applications of NANOMETM